Table 2.
Survival for Patients with High and Low ERCC1 and RRM1 Expression in the Observation and Adjuvant Chemotherapy Arms
| ERCC1 (N = 747) |
RRM1 (N = 738) |
|||||
|---|---|---|---|---|---|---|
| Low (<10) (N = 416) | High (≥10) (N = 331) | HR for high/low groups (95% CI) | Low (<10) (N = 375) | High (≥10) (N = 363) | HR for high/low groups (95% CI) | |
| OS | ||||||
| Control group | 0.77 (0.56–1.05) (P = 0.10) | 1.06 (0.77–1.46) (P = 0.74) | ||||
| No. of deaths/No. of patients | 108/195 | 85/170 | 90/179 | 98/180 | ||
| Median survival, months | 44 | 50 | 48 | 45 | ||
| 2-Year survival rate⁎ | 0.65 (0.58–0.71) | 0.72 (0.65–0.78) | 0.68 (0.61–0.75) | 0.69 (0.62–0.76) | ||
| 5-Year survival rate | 0.39 (0.32–0.47) | 0.43 (0.35–0.52) | 0.46 (0.38–0.54 | 0.38 (0.29–0.46) | ||
| Chemotherapy group | 1.07 (0.79–1.45) (P = 0.67) | 1.15 (0.84–1.57) (P = 0.38) | ||||
| No. of deaths/No. of patients | 108/221 | 88/161 | 96/196 | 101/183 | ||
| Median survival, months | 51 | 52 | 55 | 48 | ||
| 2-Year survival rate | 0.75 (0.68–0.80) | 0.76 (0.69–0.82) | 0.73 (0.67–0.79) | 0.76 (0.70–0.82) | ||
| 5-Year survival rate | 0.46 (0.39–0.53) | 0.40 (0.32–0.49) | 0.47 (0.39–0.55) | 0.39 (0.31–0.47) | ||
| HR for chemotherapy/control groups (95% CI) | 0.73 (0.55–0.96)(P = 0.02) | 1.01 (0.74–1.38)(P = 0.94) | 0.84 (0.62–1.13)(P = 0.25) | 0.91 (0.69–1.22)(P = 0.87) | ||
| Interaction P value (ERCCI or RRMI × treatment) | 0.12 | 0.69 | ||||
| DFS | ||||||
| Control group | 0.80 (0.60–1.08) (P = 0.12) | 1.08 (0.80–1.46) (P = 0.61) | ||||
| No. of events/No. of patients | 122/195 | 98/170 | 109/179 | 107/180 | ||
| Median survival, months | 33 | 39 | 34 | 37 | ||
| 2-Year survival rate | 0.57 (0.50–0.64) | 0.66 (0.58–0.72) | 0.60 (0.52–0.67) | 0.62 (0.55–0.69) | ||
| 5-Year survival rate | 0.33 (0.28–0.45) | 0.36 (0.28–0.45) | 0.35 (0.28–0.43) | 0.35 (0.28–0.43) | ||
| Chemotherapy group | 1.01 (0.76–1.34) (P = 0.97) | 1.09 (0.81–1.46) (P = 0.59) | ||||
| No. of events/No. of patients | 122/221 | 95/161 | 105/196 | 112/183 | ||
| Median survival, months | 43 | 45 | 50 | 40 | ||
| 2-Year survival rate | 0.65 (0.59–0.71) | 0.66 (0.58–0.73) | 0.65 (0.58–0.71) | 0.65 (0.58–0.72) | ||
| 5-Year survival rate | 0.41 (0.35–0.49) | 0.36 (0.28–0.45) | 0.44 (0.36–0.52) | 0.35 (0.28–0.43) | ||
| HR for chemotherapy/control groups (95% CI) | 0.76 (0.59–0.99)(P = 0.04) | 0.97 (0.72–1.30)(P = 0.82) | 0.87 (0.66–1.15)(P = 0.32) | 0.87 (0.66–1.15)(P = 0.32) | ||
| P value (ERCCI or RRMI × treatment) | 0.24 | 0.99 | ||||
⁎
Survival rate data are shown as mean (range).